Genetic tumour suppressant identified


3 September 2015

Researchers at Boston University School of Medicine have found that a protein complex can work as a tumour suppressant in cases of lymphoma, melanoma, colorectal and breast cancer.

Using bioinformatics, the team discovered that a genetic variation that prevents the APC/C complex from working is often present in the cells of melanomas. From this, they concluded that the gene, which suppresses the Cdh1 protein, is essential for controlling cell division, and thus for preventing some kinds of cancer.

Cdh1 also has an inverse relationship with PAX3, another protein known to play a role in cell reproduction. A lack of Cdh1 prevents excess PAX3 from being broken down, and can lead to the uncontrolled cell division that causes tumours.

Corresponding author Rutao Cui said: "These findings have significant implications to the field of cancer by providing important insights into molecular genetics of melanoma and could lead to the identification of novel preventive strategies and therapeutic targets for melanoma."

Posted by Jeanette Royston


Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

Find a treatment, test or scan available at:


Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.


Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...



© Spire Healthcare Group plc (2016)